ProShares Ultra NASDAQ Biotechnology
22 hedge funds and large institutions have $8.2M invested in ProShares Ultra NASDAQ Biotechnology in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
1.87% more ownership
Funds ownership: 7.24% → 9.1% (+1.9%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Holders
22
Holding in Top 10
–
Calls
$2.59M
Puts
$1.21M
Top Buyers
| 1 | +$2.43M | |
| 2 | +$785K | |
| 3 | +$508K | |
| 4 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
+$228K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$138K |
Top Sellers
| 1 | -$1.68M | |
| 2 | -$393K | |
| 3 | -$324K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$286K |
| 5 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
-$240K |